Symbols

RGLS(Delisted)

Regulus Therapeutics·NASDAQ

--(--)

Signals Analysis

Bullish signal 1

Bearish signal 0

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About RGLS

Regulus Therapeutics Inc.

A biopharmaceutical company that developing therapeutics to target microRNAs

Industry

Established Date

09/06/2007

Listing Date

10/04/2012

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.regulusrx.com

Security Type

Common stock

Office address

4224 Campus Point Court, Suite 210, San Diego , CA 92121

Business

Introduction

Regulus Therapeutics Inc., was incorporated in Delaware on September 6, 2007. The company is a clinical-stage biopharmaceutical company dedicated to the discovery and development of first-in-class drugs targeting microRNAs to treat diseases with significant medical needs.

Company Financials

EPS

RGLS has released its 2025 Q1 earnings. EPS was reported at -0.15, versus the expected -0.26, beating expectations. The chart below visualizes how RGLS has performed over recent quarters, highlighting trends in earnings surprises.